- Home
- JFR vs ARDX Comparison
JFR vs ARDX Comparison
Compare JFR & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- ARDX
- Stock Information
- Founded
- JFR 2004
- ARDX 2007
- Country
- JFR United States
- ARDX United States
- Employees
- JFR N/A
- ARDX N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- JFR Finance
- ARDX Health Care
- Exchange
- JFR Nasdaq
- ARDX Nasdaq
- Market Cap
- JFR 1.1B
- ARDX 882.9M
- IPO Year
- JFR N/A
- ARDX 2014
- Fundamental
- Price
- JFR $8.53
- ARDX $5.21
- Analyst Decision
- JFR
- ARDX Strong Buy
- Analyst Count
- JFR 0
- ARDX 9
- Target Price
- JFR N/A
- ARDX $10.50
- AVG Volume (30 Days)
- JFR 621.7K
- ARDX 4.5M
- Earning Date
- JFR 01-01-0001
- ARDX 08-04-2025
- Dividend Yield
- JFR 11.31%
- ARDX N/A
- EPS Growth
- JFR N/A
- ARDX N/A
- EPS
- JFR N/A
- ARDX N/A
- Revenue
- JFR N/A
- ARDX $386,146,000.00
- Revenue This Year
- JFR N/A
- ARDX $10.10
- Revenue Next Year
- JFR N/A
- ARDX $32.38
- P/E Ratio
- JFR N/A
- ARDX N/A
- Revenue Growth
- JFR N/A
- ARDX 83.88
- 52 Week Low
- JFR $7.61
- ARDX $3.21
- 52 Week High
- JFR $8.82
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- JFR 59.83
- ARDX 73.28
- Support Level
- JFR $8.47
- ARDX $4.08
- Resistance Level
- JFR $8.53
- ARDX $5.31
- Average True Range (ATR)
- JFR 0.04
- ARDX 0.21
- MACD
- JFR -0.00
- ARDX 0.08
- Stochastic Oscillator
- JFR 90.00
- ARDX 80.21
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.